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SUMMARY
Here, we provide a detailed protocol for synthetic lethality screens in a Jurkat T cell
leukemia line using cell death as the readoutmeasuring the combinatorial effect of a
pan-PI3K inhibitor (GDC0941) with specific gene depletion by shRNA. We describe
the use of an ultra-complex shRNA library, coverage considerations, time frames,
protocol details, and bottlenecks with images to facilitate similar approaches. We
discuss how this protocol resource can be readily adapted by investigators.
For complete details on the use and execution of this protocol, please refer to
(Mues et al., 2019).
BEFORE YOU BEGIN
Here, we describe the use of a non-adherent, human Jurkat T cell leukemia cell line
that we can easily expand to 1.6x108 cells, which can be efficiently transduced with
1.1x108 lentiviral infectious units to achieve a MOI (multiplicity of infection) of 0.7
(In general, a MOI of 0.3 -0.9 is usually recommended for screens).
1. Thaw Jurkat cell line from N2 in a 37C water bath.
2. Resuspend cells at 2x105 cells/ml with Jurkat media
CRITICAL: Keep cell density between 105 -106 cells/ml, this ensures
efficient transduction.
Figure 1A
Alternatives:Other cell lines could be used, if the lentiviral infection rate is es-
tablished before use. Identification and validation of a cell platform that allows
you to consider the previous parameters are critical. Can you obtain large
numbers of cells? Do these cells die faithfully in your assay? Can you routinely
and consistently infect your cells to efficiently introduce your shRNA- or
sgRNA- guides? In our Mues et al. study (Mues et al., 2019) we validate one
specific synthetic lethality combination in 28 different cancer cell lines, which
demonstrated that this Jurkat line is, in principal, suitable to identify synthetic
lethality that also impacts other cancer types and adherent cells.
Alternatives: We describe the use of cell death as a screening tool, but fluo-
rescent reporters can work very well too. You should design an appropriate
screening assay to answer your specific biological question.
STAR Protocols--, 100016,--, 2020 ª 2020 The Authors.
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Alternatives: We describe the use of FACS-based assays, but microscopy
could also be used. Keep in mind that the quality of experimental read-out
and its discriminating power is very important and depends strongly on the
method selected. For example, we favor FACS-based assays over microscopy
because we can apply well-defined gates with FACS. High throughput is also
an important consideration.
Alternatives: In our screen, we used a high coverage shRNA library with 2000X
coverage. There are several alternatives available (e.g., either shRNA or more
novel sgRNA, such as for CRISPRi or CRISPRa platforms, which can be used to
inhibit (CRISPRi) or activate (CRISPRa) gene expression respectively). The key
issue in choosing a library is being able to work with high coverage. This
avoids population-skewing, over- or under- estimating single target genes,
and off-target complication. Many publications use at least 1000X coverage.
KEY RESOURCES TABLE
Figure 1. Jurkat
(A) Representative image of healthy Jurkat cell line under the microscope.
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
pAkt (Ser473), h Cell Signaling Tech. CST #4058
pS6 (Ser235/236), h Cell Signaling Tech. CST #2211
Annexin V-APC eBioscience BMS306APC-20
PE Donkey Anti-Rabbit IgG Jackson Immuno 7711-116-152
Chemicals, Peptides, and Recombinant Proteins
GDC-0941 (Pictislib) Selleckchem S1065
Sodium Azide (NaN3)
calcium chloride (CaCl2 x 2H2O) Sigma-Aldrich C8106
Methanol Fisher Chemical A412
32% PFA VWR 15714-S
DMSO Fisher Chemical BP321
2-propanol Sigma-Aldrich 190764
Propidium Iodide Molecular Probes P3566
Acridine Orange Sigma-Aldrich 235474
Puromycin Dihydrochloride MP Biomedicals 0210055225
(Continued on next page)
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MATERIALS AND EQUIPMENT
Jurkat Media
RPMI with
L-Glutamine
10% FBS
1%P/S
1% HEPES
Drug Reconstitution
Reconstitute 1mg of GDC0941 at 10mM with 194 ml of DMSO
Store at -20C for long term storage.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Critical Commercial Assays
QIAamp DNA Blood Maxi Kit QIAGEN 51192
Buffer AW1 QIAGEN 19081
Buffer AW2 QIAGEN 19072
QIAquick Gel Extraction Kit QIAGEN 28115
QIAquick PCR Purification Kit QIAGEN R28104
PstI-HF New England Biolabs R3140T
HiFi Phusion polymerase New England Biolabs M0530L
Experimental Models: Cell Lines
Human: JURKAT cells Lab of Jeroen Roose N/A
Oligonucleotides
TruSeq Index Primers (The barcoding
primers are proprietary to Illumina and were
shared with the UCSF
Genomics Core with the constraint not to
publish the individual sequences.)
Illumina N/A
Recombinant DNA
UCSF EXPANDed RNAi library Lab of Michael McManus,
UCSF ViraCore
Bassik et al., 2009
Other
Flow cytometer N/A N/A
Automatic or manual cell counter N/A N/A
Water bath N/A N/A
Centrifuge for 1.5, 15, 50ml tubes and 96
well plates
N/A N/A
Vacuum system with manifold N/A N/A
Thermocycler N/A N/A
Agarose/DNA gel station N/A N/A
Cold room (4C) N/A N/A
HyClone RPMI 1640 Media with L-
Glutamine
GE Healthcare LifeScience SH30027.02
1M HEPES, 100 ml UCSF Cell culture Facility INVZR929
1.2ml Microtiter tubes ThermoFisher Scientific 3492
123count eBeads Counting Beads Invitrogen 01-1234
Roller Bottle Corning 430849
GeneRuler 1kbP Plus DNA ladder ThermoFisher Scientific SM1333
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CRITICAL: Avoid freeze/thaw cycles
FACS Buffer
PBS
2mM EDTA
2% FBS
0.09% NaN3
QIAamp DNA Blood Maxi Kit
Resuspend Protease according to manufacturer’s protocol.
Make 500ml Protease aliquots with H2O and store at -20C
Note:We recommend you order more wash buffers AW1 and AW2, which will
be used for the vacuum protocol.
STEP-BY-STEP METHOD DETAILS
Titer Drug Concentration
TIMING: 30 min (Figure 2)
This step allows you to determine what drug concentration (GDC0941) to use in your
screen.
1. Prepare 3-fold serial dilution (9mM, 3mM, 1mM, 333nM, 111nM, 37nM, 12nM,
DMSO) at 2X
a. Thaw a small aliquot of GDC0941 while you prepare tubes
b. Set up 2 tubes with 750ml of Jurkat media and 6 tubes with 500ml of Jurkat me-
dia
c. Add 1.35ml of 10mMGDC0941 to one tube containing 750ml and mix. This will
be 9 mM
d. Transfer 250 ml from 9 mM tube to a tube containing 500 ml and mix. This will be
3 mM.
e. Transfer 250 ml from 3 mM tube to a tube containing 500 ml and mix. This will be
1 mM.
f. Repeat previous dilution until 12nM tube.
Figure 2. Drug Preparation
(A) Cartoon of serial dilution to prepare 3-fold drug dilution.
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g. For DMSO control, add 1.35ml DMSO to the last tube containing 750ml
h. Transfer 200ml of each inhibitor concentration into two adjacent wells (for du-
plicates) of a 48 well plate
Analyzing Cell Proliferation with Flow Cytometry
TIMING: 2 h
This step describes how to obtain the cell counts with flow cytometry with live/dead/
apoptotic discrimination
2. Prepare Jurkat cell line.
a. Count cells according to your preferred method
b. Resuspend 2x106cells at 400x103 cells/ml with Jurkat media
c. Add 200ml of cells to 48 well plate containing inhibitors
d. Let the cells proliferate in the incubator for 3 days at 37C
3. Set up reagents for 20 samples. Final volume will be 200ml.
a. 10X CaCl2 in PBS (20mM). Table 1
b. 10X Acridine Orange (AO, 200nM) and Propidium Iodide (PI, 2mM). Add 20ml
of 10mM AO and 20ml of 100mM PI stocks to 1ml PBS. Table 1
c. 10X Annexin V–APC in FACS Buffer. 1ml of Annexin V + 19ml of FACS Buffer for
each sample.
d. 123count eBeads Counting Beads. Remember manufacturer exact counts
(106beads/ml)
4. Prepare a pre-mix transferring 200ml of each of the reagents (10X CaCl2 in PBS
(20mM), 10X AO/PI (200nM/2mM), 10X Annexin-V in FACS Buffer (1:19), eBio-
science 123 count Beads) into 1ml tube.
5. Add 80ml of the previous pre-mix into 16 1.2ml Micro titer tubes
6. Add 120ml of each well of cell proliferation experiment seeded 3 days ago into
previous 1.2ml Micro titer tubes containing the pre-mix. Keep tubes on ice.
7. Run the samples in a Flow cytometer machine (Figure 3A) with the appropriate
Lasers and filters. E.g. AO in FITC, PI in mCherry, Annexin V in APC, Beads in Pa-
cific Blue and AmCyan
Flow Cytometry Analysis
TIMING: variable
This step describes a proposal of gating strategy in order to reduce variability.
(Figure 3B)
8. No gating in FCS/SSC
9. All events in Pacific Blue and AmCyan. Gate double positive beads
10. All events in FITC and mCherry. Gate on AO+ (nucleated cells)
11. AO+ events in mCherry and APC. Make quad gate: live cells (PI-Annexin V-),
apoptotic cells (PI- Annexin V+) dead cells (PI+ Annexin V+)
12. Get counts of each parameter
Table 1. CaCl2 and Acridine Orange Solutions
[Stock]
1M CaCl2 1.47 g CaCl2 x2 H2O in 10ml
ddH20
1mM Acridine Orange (AO) 2.65 mg AO in 10ml ddH2O
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13. Cell concentration (cells/ml) = bead concentration x (cell count x bead volume) /
(bead count x cell volume). For example, Cell concentration (cells/ml) = 106
beads/ml x (cell count x 20ml) / (beads count x 120ml)
Signaling Experiment
TIMING: 2 days
This step describes how to analyze the effect of 1h of GDC0941 in PI3K signaling by
measuring levels of pAKT and pS6
14. Prepare Drug concentration as above.
15. Resuspend 8x106Jurkat cells with 4ml of Jurkat media (2x106 cells/ml)
16. Add 400ml of each GDC0941 concentration (9mM, 3mM, 1mM, 333nM, 111nM,
37nM, 12nM, DMSO) in a different well of a 12 well plate
17. Add 400ml of Jurkat cells into each well containing GDC0941. Mix well and incu-
bate for 1h at 37C.
18. Add 200ml of 10% PFA and incubate at RT for 5 min. Transfer cells to 1.5ml tube
19. Centrifuge 5 min at 500G, remove supernatant, resuspend cells by flicking.
20. Add 300ml of 90% ice-cold methanol and incubate at -20C at least 12-16h.
PAUSE POINT: Samples here can be stored at -20 for up to 2 months.
21. Add 1ml of FACS buffer and incubate 5 min to rehydrate
a. Prepare primary antibody
Figure 3. Flow Cytometry Analysis
(A) Picture of a flow machine suitable for the analysis.
(B) Representative flow cytometry panel of Live/Dead proliferation experiment. Beads are gated on
Pacific Blue vs AMcyan. Nucleated cells are gated on Acridine Orange (FITC+). Apoptotic cells are
gated on Annexin V+ Propidium Iodide (PI)-. Dead cells are gated Propidium Iodide (PI)+.
(C) Representative phospho-flow analysis of baseline pAKT (red) and pS6 (green) levels on Jurkat.
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i. pAKT S473: 495ml of FACS buffer + 5ml of pAKT antibody
ii. pS6 S235/236: 499ml of FACS buffer + 1ml of pS6 antibody
iii. Control: 500ml of FACS buffer
22. Centrifuge cells for 2 min at 2500G, remove supernatant, resuspend cells by flicking
23. Add 150ml of FACS buffer
24. Split each condition (50ml) in 3 wells of a U-shaped 96 well plate
25. Add 150ml of FACS buffer
26. Centrifuge for 2 min at 2500G, remove supernatant, resuspend cells by flicking
27. Add 50ml of each antibody mix (pAKT, pS6 and control) to each condition.
28. Incubate 30 min at RT
a. Prepare 2ary antibody
b. Donkey anti-rabbit-PE: 1386ml of FACS buffer + 14ul of antibody
29. Wash cells twice with 200ml of FACS buffer
30. Add 50ml of 2ary antibody to each well
31. Incubate 15 min in the darkness at RT
32. Wash twice with 200ml of FACS buffer at 2500G for 2 min
33. Resuspend the cells with 150ml of FACS buffer and acquire on a flow cytometer.
34. Analyze your datae.g. in histograms that depict the levels of pAktor pS6 (Figure3C).
Lentiviral Transduction
TIMING: 10–12 days
This step describes the infection of Jurkat cell line containing the shRNA library with
at least 2000X coverage. The shRNA-encoding vector has mCherry reporter gene
and Puromycin selection gene.
35. Jurkat cell line is expanded in regular flasks until desired cell number is achieved
36. Day -9: shRNA library contains 1,800 genes with 55,000 shRNAs. To use a
2000X coverage 1.1x108 lentiviral infectious units are seeded with 1.6x108 Ju-
rkat cells to achieve a MOI of 0.7 in 80ml total in a roller bottle (Figure 4A).
37. Leave cells with lentivirus 12-16h in the incubator.
38. Day -8: Next morning add 90ml of fresh Jurkat media.
Figure 4. Jurkats Containing the shRNALibrary
Are Resistant to Puromycin after Treatment
(A) Picture of a roller bottle in the roller bottle
specific incubator.
(B) Representative flow cytometry histogram of
Puromycin/mCherry selection from
untransduced cells, day -7, day -3 and day 0.
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39. Day -7: Analyze mCherry expression by flow cytometry and start treatment with
2mg/ml of Puromycin (previously tittered: protocol not described). Split cells
when necessary adding 2mg/ml of Puromycin keeping cell density between
105 and 106 cells/ml to ensure they are in exponential growth.
CRITICAL: Do not use less than 1.1x108 cells. Coverage might be
compromised
40. Day -3: Analyze mCherry expression by flow cytometry.
41. Day 0: Analyze mCherry expression by flow cytometry. Cells should be >90%
positive. (Figure 4B).
Note: If less than 90% of the cells are mCherry positive, continue the puromy-
cin selection.
42. Cryopreserve at least 1.1x108 cells at T0.
Cell Growth and Selection Screen
TIMING: 3–4 weeks
Expand Jurkat cell line with GDC0941 or DMSO for 3 weeks to allow for shRNA-
induced cell death (synthetic lethality). Note that enrichment for shRNA species
can also be picked up.
43. Day 0: Add 1.1x108 cells into 2 different roller bottles and fill up to 250ml of fresh
Jurkat media with 1mg/ml of Puromycin. One bottle will have GDC0941 at
1.4mM, the concentration at which cell growth is reduced by 20% and phos-
pho-signaling is reduced according to drug titration. 35ml of GDC0941 at
10mM will be added to the bottle. Same amount of DMSO will be added to
the control bottle
44. Day 1: Split the 250ml of each bottle of GDC0941 and DMSO into 2 roller bottles
(125 each bottle), to ensure there is not cell saturation. Add 125ml of new fresh
media to each bottle with 17.5ml of GDC0941 at 10mM or DMSO and 1mg/ml of
Puromycin.
Note: Puromycin can be reduced at 0.5-1mg/ml to maintain the selection
45. Day 3: Count and check cell viability. Split cells down to 5.5x107 cells each bot-
tle, add fresh Jurkat media up to 250ml with 1mg/ml of Puromycin and 1.4mM of
GDC0941 or DMSO.
46. Repeat previous step every two or three days according to your cell growth.
Keeping them under 2x106cells/ml
47. On day 22, snap freeze. Count cells, centrifuge 1.2x108 cells 5min at 1500rpm,
discard supernatant, transfer them into a 5ml cryovial, centrifuge and discard su-
pernatant again. Resuspend cells in remaining liquid and snap freeze at liquid
N2 for 1 min before you keep it at -80 for long term storage.
Note: we chose a 22-day screening period. This is somewhat arbitrary and
could be shortened. The reason to allow for a longer selection period here
was two-fold. First, we use a very modest concentration of PI3K inhibitor as
backdrop. Second, we wanted to be sure to catch synthetic lethality that
was not instantly but could take several days.
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PAUSE POINT: You can cryopreserve cells during the splitting days if you
would like to preserve material from time points while the screen is ongoing.
gDNA Extraction
TIMING: 2–3 h
This step describes the extraction of gDNA from frozen pellet.
48. Use the QIAamp DNA Blood Maxi Kit. Protocol is slightly modified from the
manufacturer. Before to start, warm water bath to 70C, thaw an aliquot of
Protease and set up the vacuum manifold connectors (Figure 5).
49. Thaw cell pellet at RT.
50. Resuspend cells completely when thawed.
51. Add 8.5ml of PBS and mix while transferring solution to a 50ml tube.
52. Add 500ml of Protease and mix.
53. Add 12 ml of buffer AL.
54. Invert 15 times to mix, then shake vigorously for 1 min. DO NOT VORTEX.
55. Close tube tightly and incubate 15min at 70C, shake every 5 min.
56. Add 10ml of 100% EtOH.
57. Invert 15 times to mix, then shake vigorously for 1 min. DO NOT VORTEX.
Note: Each sample is divided in 2 columns.
58. Add half of volume (15ml) to each column. Taking care not moisten the rim.
59. Open the vacuum ad let the lysate pass through the column.
60. Wash with 15ml of AW1 – 30-60min.
61. Wash with 15ml of AW2 – 15-30 min.
62. Dry each membrane individually opening the valve for 10s.
63. Wipe rim with dry clean tissue.
64. Dry all columns for 30 min with vacuum.
65. Transfer columns into 50ml tubes.
66. Add 600ml of AE buffer, incubate for 5 min, centrifuge 5min at 3500g.
67. Add 600ml of AE buffer, incubate for 5 min, centrifuge 5min at 3500g.
68. Add 400ml of AE buffer, incubate for 5 min, centrifuge 10min at 3500g.
69. Final volume 1100-1200ml.
70. Transfer elution into a 1.5ml tube.
71. Determine DNA concentration.
Figure 5. Vacuum Manifold for DNA Extraction
(A) Vacuum manifold connected to the vacuum system for DNA extraction.
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gDNA Digestion
TIMING: 16–18 h
This step describes the digest of whole gDNA to excise the band of interest.
72. In a 2ml tube add the following:
1100ml of gDNA.
123ml of CutSmart Buffer.
8ml of PstI-HF restriction enzyme.
73. Incubate 12-16h at 37C in a rotation.
74. Estimate digestion by running 2ml of digested DNA and 1ml of undigested in a
1.5% agarose gel.
75. You are expecting a smear on the digested gDNA (Figure 6A).
DNA Gel Extraction
TIMING: 2 days
This step describes how to excise the gel portion to extract the size of interest.
76. Prepare a 0.6% agarose gel in a large caster. Make sure the gel has 3 lanes. 1
big lane in the middle which will hold 1400ml and 1 to each side for the ladder.
77. Once the gel is solidified, transfer it to the cold room (4C).
78. Carefully pull out the combs and check for integrity.
79. Add 130ml of 10X DNA loading dye to digested DNA.
80. Load along with 1kb ladder and run the gel at 130V in the cold room (4C) - 1-2h.
81. Cut band of interest out of the gel. In this protocol is 2.2kb (Between 1.5 and 4kb
markers).
82. Weight the fragment of gel. From this moment we will assume the gel’s weight
is 10g.
83. Place the fragment of the gel in a 10ml syringe.
84. Push the gel slurry down using the syringe into a 50ml tube (Figure 6B).
85. Place it at -20C for at least 12-16h.
PAUSE POINT: Sample can be stored at -20C for longer if desired.
86. Thaw it at RT – 30-60 min.
87. Use QIAquick Gel extraction kit using vacuum Manifold. Little modifications of
the protocol are made.
88. Add 30 ml of QC buffer to the 50ml tube.
89. Incubate the tube at 50C for 5-10 min or until the gel is melted. Mix to
accelerate the process.
90. After the gel has dissolved completely, check that the color of the mixture is
yellow. If the mixture is orange or violet add 10 ml of 3M sodium acetate pH 5
until the solution turns yellow (Figure 6C).
91. Use 2 columns for each sample. Take a new clean 15ml tube cut the bottom part
of them with a clean blade. Making a hole. Place the tube inside the column
(Figure 6D).
92. Seal the 15ml tube and the column with parafilm in order to add the solution in
fewer steps (Figure 6E).
93. Add half of the volume (20ml) to each 15ml tube (Figure 6E).
94. Let the solution go through the column using the vacuum.
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95. Remove the 15ml tubes.
96. Wash twice with 500ml of QG buffer.
97. Wash 3 times with 800ml of PE buffer.
98. Vacuum for 5 min to dry the membrane.
99. Transfer the column to a 2ml collection tube.
100. Centrifuge at Max speed for 5 min and discard the collection tube.
Figure 6. Illustrated Steps for gDNA Extraction
(A) Representative agarose gel with undigested DNA (left) and PstI-HF digestion 12-16h.
(B) An excised piece of agarose inside 10ml syringe (left) and same piece slurred down (right).
(C) Representative picture of an orange gel extraction buffer (left) and yellow gel extraction buffer
(right).
(D) 15ml tube with the end cut (left) and same tube inside columns (right).
(E) 15ml tube with the cut end inside the columns sealed with parafilm and ensembled in the
vacuum manifold (left) same but with yellow extraction buffer (right).
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101. Place the column to a new 1.5ml low DNA bind tube.
102. Elute each column twice with 55ml of EB and combine to one tube.
103. Final volume 200ml.
104. Determine DNA concentration.
105. Run 2ml of the elution in a 1.5% agarose gel to confirm DNA extraction. A smear
is a good sign.
DNA Amplification and Barcoding
TIMING: variable
This step describes the amplification of shRNA from the proviral DNA and barcoded
for sequencing.
106. DNA concentration is adjusted to 40ng/ml
107. PCR optimization for temperature and cycles
a. Prepare small amount of primers at 10mM for optimization. TrueSeqIndex
forward and a common revers primer are used for barcode
b. PCR are performed using NEB HiFi Phusion polymerase
c. PCR pre-mix for 5 well to test temperature. Prepare on ice and add in the
following order. Table 2
d. Split 20ml to 4 different 0.2ml PCR tubes. Pre-heat the thermocycler at 98C
prior to add the tubes. Skip this step once the tubes are in the thermo-
cycler (Figure 7A)
e. Cycling protocol (Figure 7B)
Stage 1 - 98C - Forever
Stage 2 - 98C – 3 min
Stage 3; step 1 - 98C – 15s
Stage 3; step 2 - Four gradients of temperatures according to your
primers – 30s
Stage 3; step 3 - 72C – 30 s
Repeat stage 3, 29 times
Stage 4; step 1 - 72C – 5min
Stage 4; step 2 - 4C – Forever
f. Run samples at 1% agarose and choose the temperature that show the neat
270bp band
g. PCR pre-mix for 10 well to test cycles. Prepare on ice and add in the
following order. Table 4
Table 2. PCR Optimization Calculations for Temperature
Volume (ml)
H20 44
GC buffer 20
10mM dNTPs 2
10mM TrueSeqIndex forward 5
10mM TrueSeq reverse 5
DMSO 3
Phusion polymerase 1
DNA 20 (160ng/reaction)
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h. Split 20ml to 9 different 0.2ml PCR tubes. Pre-heat the thermocycler at
98C prior to add the tubes. Skip this step once the tubes are in the
thermocycler
i. Cycling protocol
Stage 1 - 98C – Forever
Stage 2 - 98C – 3 min
Stage 3; step 1 - 98C – 15s
Stage 3; step 2 - Previously step chosen temperature – 30s
Stage 3; step 3 - 72C – 30 s
Repeat stage 3, 30 times
CRITICAL: Remove from the thermocycles one tube at cycles 10, 12, 14, 16,
18, 20, 22, 24, 28 and put themon ice until the cycle reach 30. Then add all the
tubes again to the thermocycles to finish the last elongation step
Stage 4; step 1 - 72C – 5min
Stage 4; step 2 - 4C – Forever
108. Run samples at 1% agarose and choose the cycle that first shows a single 270bp
band before higher and lower band form.
109. Now you are ready to scale up reaction. Multiply previous volumes for 75x.
Table 3
110. Divide into twelve 0.2ml tubes (120ml each). Pre-heat the thermocycler at 98C
prior to add the tubes. Skip this step once the tubes are in the thermocycler
Figure 7. Indexing PCR
(A) Thermocycler with a gradient of temperatures used to choose the appropriate annealing
temperature and number of cycles for indexing.
(B) Photo of the PCR cycle used to assess the right temperature of annealing (left & right).
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111. Cycling protocol
Stage 1 - 98C - Forever
Stage 2 - 98C – 3 min
Stage 3; step 1 - 98C – 15s
Stage 3; step 2 - Temperature – 30s
Stage 3; step 3 - 72C – 30 s
Repeat stage 3, ‘‘n’’ times
Stage 4; step 1 - 72C – 5min
Stage 4; step 2 - 4C – Forever
112. Combine all PCRproducts fromprevious 12 tubes and run 15ml in a 1%agarose gel
113. Confirm there is a neat 270bp band
PCR Product Concentration
TIMING: 30 min
This step reduces the volume of the PCR reaction. QIAquick PCR purification kit is
used.
114. Mix 1.5ml of PCR reaction + 7.5ml of Buffer PB
115. If the color of the mixture is orange or violet add 10ml of 3M sodium acetate pH
5 and mix. Repeat until color of the mix will turn yellow (Figure 6C)
116. Run each sample into 2 columns. Place a column into a 2ml collection tube
117. Add 750ml of solution into each column
118. Centrifuge for 30-60s at Max speed and discard flow-through
119. Add 750ml of solution again and centrifuge until all solution run through the
columns
120. Wash twice with 1ml of PE buffer.
121. Centrifuge for 30-60s at Max speed.
122. Place the column into a new 2ml collection tube and centrifuge for 1 min to re-
move residual wash buffer.
123. Place each column in a clean low-DNA binding tube.
124. Add 55ml EB buffer to each column.
125. Incubate for 1 min at RT and centrifuge for 1 min at max speed.
126. Combine elution from both columns. Final volume will be 110ml.
PCR Purification from Agarose Gel
TIMING: 4–6h
Table 3. Scale Up PCR Calculations
Volume (ml)
H20 660
GC buffer 300
10mM dNTPs 30
10mM TrueSeqIndex forward 75
10mM TrueSeq reverse 75
DMSO 445
Phusion polymerase 15
DNA 300 (160ng/reaction)
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This step describes the isolation of PCR product from agarose gel.
Note:Different techniques can be used to isolate index DNA band from a gel.
Mues et al. (Mues et al., 2019) described a purification using polyacrylamide
gel and isolation from a gel with electro-elution. We have since had better suc-
cess with agarose gel purification, which we describe here.
127. Prepare a 0.6% agarose gel.
128. Once the gel is solidified, transfer it to the cold room (4C)
129. Add 11ml of 10X loading dye to the 110ml eluted previously
130. Load along with a ladder (i.e. GeneRuler 1kb Plus DNA Ladder) and run the gel
at 130V in the cold room (4C)
131. Cut band of interest out of the gel. In this protocol it is 270 bp fragment and
safe for extraction.
132. Weigh the fragment of gel. From this moment we will assume the gel weight
is 1g.
133. Use QIAquick Gel extraction kit using microcentrifuge protocol. Slight modifi-
cations are made.
134. Add 3 ml of QC buffer to the 15ml tube.
135. Incubate the tube at 50C for 5-10 min or until the gel is melted. Mix to accel-
erate the process.
136. After the gel has dissolved completely, check that the color of the mixture is
yellow. If mixture is orange or violet add 10 ml of 3M sodium acetate pH 5 until
the solution turns yellow (Figure 6C).
137. Add 1ml of 2-propanol to increase the yield. Only works for DNA fragments
<400bp and >4kb.
138. Place the column into 2ml collection tube.
139. Add 800ml of the solution and centrifuge for 1 min at max speed.
140. Discard flow-through and place the column back to the collection tube.
141. Add 800ml more of the solution and centrifuge for 1min. Repeat asmuch as you
need.
142. Wash once with 500ml of QG buffer.
143. Wash twice with 800ml of PE buffer.
144. Centrifuge at max speed for 2 min and discard the collection tube.
145. Place the column to a new 1.5ml low DNA bind tube.
146. Elute each column twice with 50ml of EB and combine.
147. Determine DNA concentration.
EXPECTED OUTCOMES
This protocol is meant to be used as a reference to design other screenings. We
described the detailed methodological steps, drug titration, lentiviral
Table 4. PCR Optimization Calculations for Cycles
Volume (ml)
H20 88
GC buffer 40
10mM dNTPs 4
10mM TrueSeqIndex forward 10
10mM TrueSeq reverse 10
DMSO 6
Phusion polymerase 2
DNA 40 (160ng/reaction)
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transduction, DNA extraction and amplification to inform the reader what to
expect. The ‘‘Before you begin’’ section contains considerations that are important
when one aims to make adaptations to the described screen. If the considerations
of cell line of choice, rigorous screening assay (e.g. cell death), and higher than
1000x coverage are followed properly, the research can expect to successfully
identify synthetic lethality pairs, as we did in our Mues et al. study (Mues et al.,
2019).
LIMITATIONS
This specific protocol cannot be adapted to all cell lines. The use of adherent cell
lines will need a different approach for expansion of cell numbers, lentiviral transduc-
tion, and/or monitoring cell growth. Cell doubling times, confluency of adherent
cells, available growth factors, and frequency of drug administration should be
considered for each individual cell type of choice.
Library coverage is always a limitation; the higher the level of coverage, the lower the
noise to data ratio, and the more confident the generated data sets become. Usually
1000X coverage is assumed as sufficient for experiments using libraries. In our Mues
et al. study (Mues et al., 2019) we used 2000X coverage to increase the number of
shRNA in the screening and obtain more statistical power. A screen should be de-
signed where aspects like manageable set-up and affordable experimentation are
rationally weighed against the highest possible coverage. A popular solution to
this dilemma is to perform screen for families of genes, a selection of signaling path-
ways, or a collection of cell biological processes instead of whole genome screens.
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